NYSE:MTNB

Matinas Biopharma Holdings Stock News

Healthcare > Biotechnology

Buy MTNB

*Your capital is at risk

$0.778

+0.0120 (+1.57%)

At Close: Jun 03, 2026

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

05:00pm, Friday, 03'rd Apr 2026

BEDMINSTER, N.J., April 03, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on April 2, 2026, it received a notice (the “Noti

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

07:00am, Tuesday, 11'th Mar 2025

BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugebo

Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

05:00pm, Thursday, 13'th Feb 2025

BEDMINSTER, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) (the “Company”) today announced that the Company entered into a securities purchase agree

Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair

07:30am, Friday, 07'th Feb 2025

BEDMINSTER, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of Evelyn D'An to its Board of Directors as an independent di

Matinas BioPharma Receives NYSE Noncompliance Notice

05:15pm, Friday, 10'th Jan 2025

BEDMINSTER, N.J. , Jan. 10, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that on January 6, 2025, it received a NYSE American LLC notice indicating that th

Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction

06:30am, Thursday, 31'st Oct 2024

BEDMINSTER, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that negotiations under the previously disclosed non-binding term sheet regarding g

Matinas BioPharma Holdings, Inc. (MTNB) Q2 2024 Earnings Call Transcript

09:40pm, Wednesday, 14'th Aug 2024

Matinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Jody Cain – LHA Investor Relations Jerry Jabbour – Chief Executive Of

Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update

04:05pm, Wednesday, 14'th Aug 2024

Signs non-binding term sheet granting global rights to develop and commercialize oral MAT2203 for invasive aspergillosis and potentially other invasive fungal infections

Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024

07:00am, Wednesday, 07'th Aug 2024

BEDMINSTER, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies us

Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program

08:30am, Monday, 24'th Jun 2024

BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies us

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by